USPTO serial 76365742
GENFIT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 27, 2004
- Examiner
- MCMORROW, RONALD G
- Law office
- GENERIC WEB UPDATE
What this means
Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.
Need help with GENFIT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ronald M. Kachmarik
Ronald M. Kachmarik Cooper Legal Group LLC1388 Ridge Road, Unit 1Hinckley, OH 44233UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in the treatment of cardiovascular diseases, dermatological diseases, metabolic disorders, inflammatory disorders, skin and mucosal disorders, disorders in the central nervous system, infections, cancers and oncological disorders, immunodeficiency and immunologic disorders, asthma, allergies, lipidic disorders, obesity and diabetes;[ veterinary pharmaceutical preparations for use in the treatment of cardiovascular diseases, dermatological diseases, metabolic disorders, inflammatory disorders, skin and mucosal disorders, disorders in the central nervous system, cancers, and oncological disorders, immunodeficiency and immunologic disorders, asthma, allergies, lipidic disorders, obesity and diabetes; sanitary preparations for diagnosis and for acute and chronic care, namely, antibiotic, antibacterial, antiviral and antifungal agents for elimination or reduction of germs, bacteria, viruses and fungi;] chemical preparations for medical, pharmaceutical or[ veterinary] diagnostic use; enzymatic preparations for medical, pharmaceutical [or veterinary] use; biological preparations, namely, antibodies and fragments of antibodies for laboratories, diagnostics, and analytics for human[ and veterinary] medical diagnostic use; pharmaceutical preparations for the treatment of skin conditions, [medicated skin care preparation for pharmaceutical use; medicated sunburn preventing products, namely, creams, oils, lotions, gels, for pharmaceutical use; slimming medical preparations;] cultures of microorganisms for medical, pharmaceutical [and veterinary ]use; media for bacteriological cultures; nutrients for use in medical, pharmaceutical [and veterinary research;] cell preparations for medical, pharmaceutical [or veterinary use,] in particular for gene therapy and cell therapy; [kits consisting primarily of culture media, culture boxes, culture additives, and diagnostic reagents for the preparation of cells or for the selection of biologically active compounds for medical, pharmaceutical or veterinary laboratory testing, or for medical or veterinary diagnostic use; diagnostic and biological preparations and cultures of microorganisms and cells for clinical or medical laboratory use; reagents for medical, veterinary and diagnostic use, diagnosis products, namely,] reagents for medical [or veterinary use;] chemical and biological reagents for clinical or medical laboratory use;[ diagnostic preparations for clinical or medical laboratory use;] diagnosis reagents for medical[, veterinary] use[ and in vitro use in biochemistry,] clinical chemistry and microbiology[; dietetic substances, namely, dietary supplements and food supplements for medical use; dietetic foodstuffs adapted for medical use] | ACTIVE | — |
| 042 | Pharmaceutical research and development of new drug products for others; scientific, biological and medical research in the fields of pharmacology, analytical chemistry, biochemistry, immunology, genetic, medicinal chemistry, drug development of new drug products for others; scientific, biological and medical research in the field of pharmacology, analytical chemistry, biological and medical research in the field of pharmacology, analytical chemistry, biochemistry, immunology, genetic, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology, chemical, biochemical and biotechnological analysis; basic and applied scientific research; technical research, namely screening and selection of molecules; validation of biological targets; development and validation of biological tests, cell tests, and genetic tests, identifying, characterizing, validating, and development biologically active molecules through the se of functional genomics; analysis of biological substances in biological fluids; technical consultation in the field of pharmaceuticals; legal services in the field of scientific research, medical sciences and intellectual property rights; patent agency and licensing; computer programming in the field of scientific research, medical sciences and intellectual property rights; patent agency and licensing; computer programming in the field of scientific research and for the pharmaceutical industry; surveying and engineering; chemical analysis in the field of pharmacology; technical consultation in the field of pharmacology; consultation, not connected with the conduct of business, in the fields of scientific research and therapy; research and development of new pharmaceutical products for third parties; providing an online electronic computer database in the field of scientific information | ACTIVE | — |
| 044 | Providing an online electronic computer database in the field of medical and pharmaceutical information | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 29, 2024 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Mar 29, 2024 | RNL2 | REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Mar 29, 2024 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Mar 29, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Nov 6, 2023 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Jul 27, 2023 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Sep 16, 2014 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Sep 16, 2014 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Sep 16, 2014 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Aug 13, 2014 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 25, 2014 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Aug 13, 2010 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Aug 11, 2010 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 22, 2010 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Feb 20, 2009 | CORV | REVIEW OF CORRESPONDENCE COMPLETE | — |
| Feb 2, 2009 | PAPER RECEIVED | — | |
| Jul 27, 2004 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 10, 2004 | PAPER RECEIVED | — | |
| May 4, 2004 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 14, 2004 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 2, 2003 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 20, 2003 | PAPER RECEIVED | — | |
| Oct 16, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 27, 2003 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 16, 2003 | CFIT | CASE FILE IN TICRS | — |
| Jul 9, 2003 | 1.BD | Sec. 1(B) CLAIM DELETED | — |
| Jul 9, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 9, 2003 | PAPER RECEIVED | — | |
| Jan 10, 2003 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Nov 13, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 13, 2002 | PAPER RECEIVED | — | |
| Nov 8, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 17, 2002 | DOCK | ASSIGNED TO EXAMINER | — |
| May 8, 2002 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 29, 2002 | PAPER RECEIVED | — | |
| Apr 19, 2002 | DOCK | ASSIGNED TO EXAMINER | — |